We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+9.48%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$34.5B
AUM Growth
+$1.76B
(+5.4%)
Cap. Flow
-$769M
Cap. Flow
% of AUM
-2.23%
Top 10 Holdings %
Top 10 Hldgs %
26.77%
Holding
1,963
New
176
Increased
1,051
Reduced
620
Closed
112
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Albemarle
ALB
|
+$68.7M |
| 2 |
GE HealthCare
GEHC
|
+$28.6M |
| 3 |
ON Semiconductor
ON
|
+$28.1M |
| 4 |
Caterpillar
CAT
|
+$22.6M |
| 5 |
IBM
IBM
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$94.9M |
| 2 |
Apple
AAPL
|
+$91M |
| 3 |
West Pharmaceutical
WST
|
+$69M |
| 4 |
FISV
Fiserv Inc
FISV
|
+$61.8M |
| 5 |
Amazon
AMZN
|
+$55.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Industrials | 12.05% |
| 3 | Consumer Staples | 10.74% |
| 4 | Consumer Discretionary | 10.51% |
| 5 | Healthcare | 9.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALLK
1751
DELISTED
Allakos
ALLK
| $62.1K | ﹤0.01% |
+14,246
| New | +$64.1K |
|
1752
Arbutus Biopharma
ABUS
$875M
| $62.1K | ﹤0.01% |
26,982
+2,763
| +11% | +$7.19K |
|
|
NXDR
1753
Nextdoor Holdings
NXDR
$843M
| $61.7K | ﹤0.01% |
+18,932
| New | +$47K |
|
1754
OmniAb
OABI
$304M
| $61K | ﹤0.01% |
+12,127
| New | +$49.2K |
|
|
ORGN
1755
DELISTED
Origin Materials
ORGN
| $58.8K | ﹤0.01% |
460
+48
| +12% | +$6.18K |
|
1756
OraSure Technologies
OSUR
$281M
| $58.2K | ﹤0.01% |
11,616
+1,187
| +11% | +$7.13K |
|
1757
Atea Pharmaceuticals
AVIR
$385M
| $57.5K | ﹤0.01% |
15,366
+607
| +4% | +$2.27K |
|
1758
Cerus
CERS
$575M
| $56.8K | ﹤0.01% |
23,079
+2,768
| +14% | +$6.58K |
|
1759
Nautilus Biotechnolgy
NAUT
$220M
| $56.7K | ﹤0.01% |
14,646
+378
| +3% | +$1.09K |
|
|
IAUX
1760
i-80 Gold Corp
IAUX
$1.2B
| $56.5K | ﹤0.01% |
+25,126
| New | +$59.2K |
|
1761
Erasca
ERAS
$6.83B
| $55.9K | ﹤0.01% |
20,249
+2,193
| +12% | +$6.25K |
|
|
GBIO
1762
DELISTED
Generation Bio
GBIO
| $55.8K | ﹤0.01% |
+1,014
| New | +$46.5K |
|
1763
Lexicon Pharmaceuticals
LXRX
$1.03B
| $55.7K | ﹤0.01% |
24,315
+1,429
| +6% | +$3.79K |
|
1764
TETRA Technologies
TTI
$1.26B
| $55.1K | ﹤0.01% |
16,303
+1,651
| +11% | +$4.78K |
|
1765
PLAYSTUDIOS Inc
MYPS
$82.2M
| $54.6K | ﹤0.01% |
+11,129
| New | +$48.7K |
|
1766
Sutro Biopharma
STRO
$366M
| $54.6K | ﹤0.01% |
1,173
+140
| +14% | +$6.97K |
|
1767
SIGA Technologies
SIGA
$224M
| $53.6K | ﹤0.01% |
10,604
-4
| -0% | -$23 |
|
1768
Vaalco Energy
EGY
$593M
| $52.7K | ﹤0.01% |
14,019
+1,511
| +12% | +$6.17K |
|
1769
SGHC Ltd
SGHC
$7.31B
| $51.5K | ﹤0.01% |
+17,748
| New | +$62.7K |
|
1770
Solid Power
SLDP
$472M
| $51.2K | ﹤0.01% |
20,160
+4,554
| +29% | +$10.5K |
|
1771
Wave Life Sciences
WVE
$1.12B
| $51.2K | ﹤0.01% |
+14,056
| New | +$56.8K |
|
1772
W&T Offshore
WTI
$546M
| $49.5K | ﹤0.01% |
12,790
+1,661
| +15% | +$7.14K |
|
1773
Amneal Pharmaceuticals
AMRX
$5.74B
| $49.1K | ﹤0.01% |
15,854
+3,733
| +31% | +$7.95K |
|
|
KYNB
1774
Kyntra Bio
KYNB
$28.6M
| $49K | ﹤0.01% |
726
+53
| +8% | +$21.9K |
|
1775
iHeartMedia
IHRT
$553M
| $48.6K | ﹤0.01% |
13,358
-832
| -6% | -$2.77K |
|
Similar funds
ProShare Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, ProShare Advisors held 1,963 positions worth $34.5B, up 5.4% from $32.7B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
ProShare Advisors's Q2 2023 filing shows 176 new, 1,051 increased, 620 reduced and 112 closed positions. Its largest new stake was Artesian Resources: 162,581 shares worth $7.68M. The largest sale was Microsoft, an estimated $94.9M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Industrials and Consumer Staples.
- ProShare Advisors's largest Q2 2023 buy was Artesian Resources: 162,581 shares worth $7.68M.
- ProShare Advisors added most to Albemarle in Q2 2023, an estimated $68.7M increase.
- ProShare Advisors's biggest Q2 2023 reduction was Microsoft, cutting an estimated $94.9M.
- ProShare Advisors fully exited Rivian in Q2 2023, selling an estimated $11.9M.
- ProShare Advisors's ten largest holdings make up 27% of its $34.5B portfolio in Q2 2023.
- ProShare Advisors opened 176 new positions and closed 112 in Q2 2023.
- ProShare Advisors's portfolio value rose 5.4% quarter-over-quarter to $34.5B.
Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.